Fierce Pharma
DECEMBER 2, 2024
Robert F. Kennedy Jr.’s appointment last month to lead the U.S. Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.
MedCity News
DECEMBER 22, 2024
Dexcom recently became the first medical device company to embed generative AI into a continuous glucose monitor. Adding generative AI to the companys Stelo glucose monitor will give users more personalized recommendations about how to improve their metabolic health, said Dexcom COO Jake Leach. The post Dexcom Adds Generative AI Platform to Its Over-the-Counter CGM appeared first on MedCity News.
pharmaphorum
DECEMBER 3, 2024
The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements
Pharmaceutical Technology
DECEMBER 9, 2024
Shares in WuXi AppTec, one of those implicated in the Chinese biotech blacklisting legislation, surged following the omission.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Impetus Digital
DECEMBER 23, 2024
Pharma-exclusive Webinar: The 2025 Pharma Toolkit for Virtual Medical Education About the webinar Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders. This transformative series will showcase the 2025 Pharma Toolkit for Virtual Medical Education, revealing groundbreaking virtual tools and strategies set to revolutionize how we engage and educate HCPs, patients, and teams.
PharmaVoice
DECEMBER 17, 2024
Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
DECEMBER 19, 2024
AI should augment, not replace, human provider expertise. Explainability empowers healthcare professionals to work in tandem with AI, ensuring that patients receive the most accurate and informed care. The post Unlocking AI Explainability for Trustworthy Healthcare appeared first on MedCity News.
Healthcare Success
DECEMBER 10, 2024
Did you know Google changes its algorithm up to 200 times a day? Yet many healthcare organizations still rely on SEO strategies and tactics that were "best practices" a decade ago. Its no surprise that countless healthcare providers and other businesses are seeing drops in rankings and traffic after Google's Helpful Content Update. To help you navigate these changes and learn what you need to update, I invite you to listen to this podcast featuring Brandon Schakola.
Pharmaceutical Technology
DECEMBER 24, 2024
The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.
European Pharmaceutical Review
DECEMBER 19, 2024
With the life sciences and healthcare sectors increasing integration of artificial intelligence (AI) into their infrastructure, according to research by GlobalData, one-third of healthcare professionals considered data privacy is the primary obstacle, citing challenges such as robust safeguards, workflow integration, and stakeholder acceptance [being] essential to ensure AIs ethical implementation and long-term success. 1 These concerns are held alongside the promise of this technology and its p
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PM360
DECEMBER 20, 2024
Established in 2012, PM360 introduced the first-ever issue focused entirely on our industrys latest innovations. Categories explore every sector of the healthcare industry, from life sciences to marketing. PM360 would like to welcome you to the new age of innovation with our illuminating Innovations Issue. This yearly special issue has served as your go-to guide for the most interesting advancements in our industry over the past 13 years, by featuring a focussed view of 11 different areas in hea
Fierce Pharma
DECEMBER 17, 2024
Its not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisks diabetes superstar Ozempic and blindness? | After the recent release of two independent studies from the University of Southern Denmark suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the Danish Medicines Agency has asked European officials to investigate.
MedCity News
DECEMBER 26, 2024
Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics. The post The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender appeared first on MedCity News.
pharmaphorum
DECEMBER 4, 2024
Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
Pharmaceutical Technology
DECEMBER 23, 2024
Lillys Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.
European Pharmaceutical Review
DECEMBER 11, 2024
LOG Pharma Primary Packaging is set to present its new barrier eco line at Pharmapack Europe 2025. The new bottles for pharmaceuticals offer optimal oxygen scavenging. Our R&D team has developed a series of barrier bottles that provide exceptional protection against oxygen and moisture while being environmentally friendly and reducing costs significantly, stated LOGs Chief Executive Officer Shaul Bassi.
PharmaVoice
DECEMBER 4, 2024
Dr. Marty Makary’s conflicts of interest could come into question before he is confirmed as the next FDA commissioner.
Fierce Pharma
DECEMBER 13, 2024
Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that involve young children, experts from an FDA advisory panel expressed their | An FDA advisory committeeexamining the halt of a trial of two Moderna respiratory syncytial virus (RSV) vaccines because of severe lower respiratory tract infections (LRTIs)echoed frustration in knowledge gaps about the disease and said that more testing is needed.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
DECEMBER 8, 2024
After the FTC filed a lawsuit in September, accusing the three major pharmacy benefit managers of anticompetitive rebating practices related to insulin, the defendants reversed roles and became plaintiffs. In November, they countersued the agency, arguing that its lawsuit is unconstitutional. The post The Big 3 PBMs are Countersuing the FTC. Does Their Argument Have Any Teeth?
pharmaphorum
DECEMBER 27, 2024
WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum
Pharmaceutical Technology
DECEMBER 18, 2024
Eli Lilly and EVA Pharma have announced approval from the Egyptian Drug Authority for the human insulin glargine injection.
PharmaTimes
DECEMBER 11, 2024
Promising results set stage for European marketing authorization
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmaVoice
DECEMBER 13, 2024
Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.
Fierce Pharma
DECEMBER 19, 2024
The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. | The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. The agencys move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound.
MedCity News
DECEMBER 4, 2024
Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications. The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test appeared first on MedCity News.
pharmaphorum
DECEMBER 24, 2024
Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
DECEMBER 18, 2024
Abera and Orexo have entered a partnership to develop and test the powder formulations of the formers vaccine candidates.
Pharmaceutical Commerce
DECEMBER 6, 2024
Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.
PharmaVoice
DECEMBER 2, 2024
Intrinsic Medicines is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.
Fierce Pharma
DECEMBER 4, 2024
AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the count | AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the country.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Expert insights. Personalized for you.
352 
Let's personalize your content